Stifel Financial Corp Cuts Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Stifel Financial Corp decreased its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 8.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,641 shares of the company’s stock after selling 2,682 shares during the period. Stifel Financial Corp’s holdings in Apellis Pharmaceuticals were worth $797,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Wolverine Asset Management LLC purchased a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter worth approximately $27,000. True Wealth Design LLC purchased a new stake in Apellis Pharmaceuticals during the third quarter worth $27,000. Capital Performance Advisors LLP purchased a new position in shares of Apellis Pharmaceuticals in the third quarter valued at $56,000. KBC Group NV raised its stake in shares of Apellis Pharmaceuticals by 34.8% during the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after buying an additional 679 shares during the last quarter. Finally, nVerses Capital LLC boosted its position in shares of Apellis Pharmaceuticals by 300.0% in the 2nd quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock worth $107,000 after buying an additional 2,100 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on APLS. Mizuho cut their target price on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a research report on Thursday, October 24th. Piper Sandler reduced their target price on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 6th. Needham & Company LLC dropped their price target on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Wells Fargo & Company reduced their price objective on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Finally, Evercore ISI upgraded Apellis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, October 31st. Eight research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.94.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ APLS opened at $33.32 on Wednesday. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $24.34 and a fifty-two week high of $73.80. The business has a 50 day moving average price of $30.43 and a two-hundred day moving average price of $34.44. The firm has a market cap of $4.14 billion, a PE ratio of -16.41 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same quarter last year, the firm posted ($1.17) EPS. The firm’s quarterly revenue was up 78.3% on a year-over-year basis. Sell-side analysts expect that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current fiscal year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).